106 related articles for article (PubMed ID: 28578024)
1. Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9.
Taylor RP; Lindorfer MA; Cook EM; Beurskens FJ; Schuurman J; Parren PWHI; Zent CS; VanDerMeid KR; Burack R; Mizuno M; Morgan BP
Clin Immunol; 2017 Aug; 181():24-28. PubMed ID: 28578024
[TBL] [Abstract][Full Text] [Related]
2. Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.
Cook EM; Lindorfer MA; van der Horst H; Oostindie S; Beurskens FJ; Schuurman J; Zent CS; Burack R; Parren PW; Taylor RP
J Immunol; 2016 Sep; 197(5):1762-75. PubMed ID: 27474078
[TBL] [Abstract][Full Text] [Related]
3. Mortalin/GRP75 binds to complement C9 and plays a role in resistance to complement-dependent cytotoxicity.
Saar Ray M; Moskovich O; Iosefson O; Fishelson Z
J Biol Chem; 2014 May; 289(21):15014-22. PubMed ID: 24719326
[TBL] [Abstract][Full Text] [Related]
4. Several epitopes on native human complement C9 are involved in interaction with the C5b-8 complex and other C9 molecules.
Kontermann R; Deppisch R; Rauterberg EW
Eur J Immunol; 1990 Mar; 20(3):623-8. PubMed ID: 1690659
[TBL] [Abstract][Full Text] [Related]
5. CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.
Oostindie SC; van der Horst HJ; Lindorfer MA; Cook EM; Tupitza JC; Zent CS; Burack R; VanDerMeid KR; Strumane K; Chamuleau MED; Mutis T; de Jong RN; Schuurman J; Breij ECW; Beurskens FJ; Parren PWHI; Taylor RP
Haematologica; 2019 Sep; 104(9):1841-1852. PubMed ID: 30792198
[TBL] [Abstract][Full Text] [Related]
6. Comparison of channels formed by poly C9, C5b-8 and the membrane attack complex of complement.
Zalman LS; Müller-Eberhard HJ
Mol Immunol; 1990 Jun; 27(6):533-7. PubMed ID: 1696352
[TBL] [Abstract][Full Text] [Related]
7. Complement lysis of U937, a nucleated mammalian cell line in the absence of C9: effect of C9 on C5b-8 mediated cell lysis.
Morgan BP; Imagawa DK; Dankert JR; Ramm LE
J Immunol; 1986 May; 136(9):3402-6. PubMed ID: 3514758
[TBL] [Abstract][Full Text] [Related]
8. Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells.
Klitgaard JL; Koefoed K; Geisler C; Gadeberg OV; Frank DA; Petersen J; Jurlander J; Pedersen MW
Br J Haematol; 2013 Oct; 163(2):182-93. PubMed ID: 23927424
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9.
Rollins SA; Zhao J; Ninomiya H; Sims PJ
J Immunol; 1991 Apr; 146(7):2345-51. PubMed ID: 1706395
[TBL] [Abstract][Full Text] [Related]
10. Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells.
Lindorfer MA; Cook EM; Tupitza JC; Zent CS; Burack R; de Jong RN; Beurskens FJ; Schuurman J; Parren PW; Taylor RP
Mol Immunol; 2016 Feb; 70():13-23. PubMed ID: 26690706
[TBL] [Abstract][Full Text] [Related]
11. Killing of human melanoma cells by the membrane attack complex of human complement as a function of its molecular composition.
Martin DE; Chiu FJ; Gigli I; Müller-Eberhard HJ
J Clin Invest; 1987 Jul; 80(1):226-33. PubMed ID: 3597774
[TBL] [Abstract][Full Text] [Related]
12. Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement.
Baig NA; Taylor RP; Lindorfer MA; Church AK; Laplant BR; Pavey ES; Nowakowski GS; Zent CS
Leuk Lymphoma; 2012 Nov; 53(11):2218-27. PubMed ID: 22475085
[TBL] [Abstract][Full Text] [Related]
13. Does complement kill E. coli by producing transmural pores?
Born J; Bhakdi S
Immunology; 1986 Sep; 59(1):139-45. PubMed ID: 3530981
[TBL] [Abstract][Full Text] [Related]
14. Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease.
Falk RJ; Dalmasso AP; Kim Y; Tsai CH; Scheinman JI; Gewurz H; Michael AF
J Clin Invest; 1983 Aug; 72(2):560-73. PubMed ID: 6348093
[TBL] [Abstract][Full Text] [Related]
15. Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage.
Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
J Immunol; 1983 Nov; 131(5):2570-5. PubMed ID: 6355297
[TBL] [Abstract][Full Text] [Related]
16. Multimeric C9 within C5b-9 deposits in unique locations in the cell wall of Salmonella typhimurium.
Joiner KA; Tartanian AB; Hammer CH; Schweinle JE
J Immunol; 1989 Jun; 142(12):4450-7. PubMed ID: 2656866
[TBL] [Abstract][Full Text] [Related]
17. Complement channels in membranes: inhibition with a monoclonal antibody to a neoantigen of polymerized C9.
Dalmasso AP; Benson BA; Falk RJ
Biochem Biophys Res Commun; 1984 Dec; 125(3):1013-9. PubMed ID: 6517929
[TBL] [Abstract][Full Text] [Related]
18. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.
Rollins SA; Sims PJ
J Immunol; 1990 May; 144(9):3478-83. PubMed ID: 1691760
[TBL] [Abstract][Full Text] [Related]
19. Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL.
Middleton O; Cosimo E; Dobbin E; McCaig AM; Clarke C; Brant AM; Leach MT; Michie AM; Wheadon H
Leukemia; 2015 Jan; 29(1):107-14. PubMed ID: 24787488
[TBL] [Abstract][Full Text] [Related]
20. Quantification of complement C5b-9 binding to cells by flow cytometry.
Moskovich O; Fishelson Z
Methods Mol Biol; 2014; 1100():103-8. PubMed ID: 24218253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
